Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President & Chief Financial Officer Steve Wargacki - Senior Vice President, Research & Development Ken Marshall - Senior Vice President & Chief Commercial Officer Carl Kraus - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities François Briseboi ...

Q3 2023 Earnings Supplemental Materials November 6, 2023 Advancing medicines. Solving problems. Improving lives. 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Senior Vice President, Research and Development Ken Marshall - Senior Vice President, Chief Commercial Officer Carl Kraus - Chief Medical Officer Conference Call Participants Jason Butler - JMP François Brisebois - Oppenheim ...

Q2 2023 Earnings Supplemental Materials August 7, 2023 Advancing medicines. Solving problems. Improving lives. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of Incor ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Senior Vice President, Research and Development Ken Marshall - Senior Vice President, Chief Commercial Officer Conference Call Participants Jason Butler - JMP Securities Francois Brisebois - Oppenheimer Thomas Flaten - Lake Str ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commiss ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ C ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2022 Results Conference Call March 8, 2023 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Head of R&D Ken Truitt - Chief Medical Officer Ken Marshall - Chief Commercial Officer Conference Call Participants Francois Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Ram Selvaraju - HC Wainwright James M ...